Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1995-06-02
1997-07-22
Daus, Donald G.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514323, 514339, 514374, 548238, 548427, 546200, 5462767, C07D20960
Patent
active
056504276
ABSTRACT:
A compound of Formula I ##STR1## or pharmaceutically acceptable salts of Formula I, where R.sup.1 is H, C.sub.1 -C.sub.3 alkyl, --(CH.sub.2).sub.n CONH.sub.2 where n is 2 to 6, (CH2).sub.n -1-(4,4-dimethylpiperidine-2,6-dione-yl), or cyclopropylmethyl;
R.sup.2 is hydrogen, C.sub.1 -C.sub.8 alkyl, C.sub.3 -C.sub.8 cycloalkyl or combined with R.sup.1 to form a C.sub.3 -C.sub.8 cycloalkyl, C.sub.2 -C.sub.8 alkenyl, C.sub.2 -C.sub.8 akynyl, (CH.sub.2).sub.n --X--Ar where X is O, S, or NH, 3,3,3-trifluoropropyl, --(CH.sub.2).sub.m --R.sup.9 where m is 2 or 3 and R.sup.9 is phenyl, 2-thiophenyl or 3-thiophenyl; R.sup.3 is hydrogen, C.sub.1 -C.sub.3 alkyl, 2,2,2-trifluoroethyl, 3,3,3-trifluoropropyl, formyl, CN, halogen, CH.sub.2 OR.sup.2, C(O)C(O)OR.sup.1, C(O)CO NR.sup.1 R.sup.2, --(CH.sub.2).sub.q --NR.sup.1 R.sup.2 where q is 0 to 5, C.dbd.NOR.sup.2, 2(4,5-dihydro)oxazolyl, or COR.sup.10 where R.sup.10 is H, R.sup.1, NR.sup.1 R.sup.2 or CF.sub.3 ; R.sup.4 is hydrogen, C.sub.1 -C.sub.3 alkyl, cyclopropylmethyl, CF.sub.3, 2,2,2-trifluoroethyl, CN, CONR.sup.1 R.sup.2, .dbd.O, 2(4,5-dihydro)imidazolyl, 2(4,5-dihydro)oxazolyl, 2-oxazolyl, 3-oxadiazolyl, or 3,3,3-trifluoropropyl; R.sup.5 is hydrogen, R.sup.1, OCH.sub.3, C(O)CH.sub.3 or C(O)OR.sup.1 ; X is (a) a valence bond, (b) CH.sub.2, or (c) O, S or NR.sup.5 where R.sup.5 is H, C.sub.1 -C.sub.8 alkyl, C.sub.3 -C.sub.8 cycloalkyl, benzyl, COR.sup.6 where R.sup.6 is a C.sub.1 -C.sub.3 alkyl, phenyl, or CONR.sup.7 R.sup.8 where R.sup.7 and R.sup.8 are independently H or C.sub.1 -C.sub.3 alkyl; and
Z is a hydrogen or halogen; provided that when X is CH.sub.2, at least one of R.sub.3 and R.sub.4 is other than hydrogen or C.sub.1 -C.sub.3 alkyl. The compounds of Formula I are suitable for treating disorders of the central nervous system, particularly as 5-HT.sub.1A receptor agonists.
REFERENCES:
patent: 4060626 (1977-11-01), Hrstka et al.
patent: 4370341 (1983-01-01), Asselin et al.
patent: 4510157 (1985-04-01), Asselin et al.
patent: 4600626 (1986-07-01), Hrstka et al.
patent: 4959479 (1990-09-01), Nagawa
patent: 5223527 (1993-06-01), Watjen et al.
patent: 5302599 (1994-04-01), Ennis et al.
patent: 5318967 (1994-06-01), Bruderer et al.
patent: 5486611 (1996-01-01), Lin et al.
patent: 5491236 (1996-02-01), Lin
Shagalov, L.B. et al., "Benzindoles. 17. Vilsmeier reaction in angular tetrahydrobenzindoles," CA 91:56747v for Khim. Geterotsikl. Soedin. 3:360-65 (1979).
Shagalov, L.B. et al., "Benzindoles. XIV. Synthesis of angular tetrahydro[4,5]-and [6,7]benzindoles," CA 89:146703r for Khim. Geterotsikl. Soedin. 5:634-40 (1978).
Asselin, A.A. et al., "Drug Design via Pharmacophore Identification. Dopaminergic Activity of 3H-Benz[e]indol-8-amines and Their Mode of Interaction with the Dopamine Receptor," J. Med. Chem. 29:648-54 (1986).
Wikstrom, H. et al., "Resolved 6,7,8,9-Tetrahydro-N,N-dimethyl-3H-benz[e]indol-8-amine: Central Dopamine and Serotonin Receptor Stimulating Properties," J. Med. Chem. 32:2273-76 (1989).
Nichols, D.E. et al., "Synthesis and Evaluation of N,N-Di-n-propyltetrahydrobenz[f]indol-7-amine and Related Congeners as Dopaminergic Agonists," J. Med. Chem. 32:2128-34 (1989).
Ennis et al. Jour. Med. Chem vol. 38, pp. 2217-2230 (1995).
Stjernlof et al. Jour Med. Chem vol. 38 pp. 2202-2216 (1995).
Asselin, Jour. Med Chem., vol. 29, pp. 648-654 (1986).
Wikstrom, Jour Med Chem vol. 32 pp. 2273-2276 (1989).
Andersson Bengt Ronny
Carlsson Per Arvid Emil
Elebring Stig Thomas
Ennis Michael Dalton
Haadsma-Svensson Susanne R.
Corneglio Donald L.
Daus Donald G.
The Upjohn Company
LandOfFree
Centrally acting 6,7,8,9-tetrahydro-3H-benz(e) indole heterocycl does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Centrally acting 6,7,8,9-tetrahydro-3H-benz(e) indole heterocycl, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Centrally acting 6,7,8,9-tetrahydro-3H-benz(e) indole heterocycl will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1560258